Obagi Medical Products, Valeant Pharmaceuticals deal

Valeant completed its tender offer to acquire skin disorder company Obagi for $24 per share, which values Obagi at $418.4 million. At April 25, about 14.7 million shares, or about 84.12%, had been tendered. Valeant completed the acquisition via a short-form merger. ...